Shanghai-based Sequanta Technologies, a leading multi-omics research and clinical service provider, has announced a strategic partnership with US firm Element Biosciences. With the integration of Element’s sequencing platform, the AVITI system, Sequanta is poised to enhance its focus on single-cell applications. The terms of the financial agreement have not been disclosed.
Element AVITI Sequencer’s Breakthrough Plan and Sequanta’s Validation
In January 2023, Dr. He Min, CEO of Element Biosciences, officially announced the breakthrough plan for the Element AVITI sequencer at the J.P. Morgan conference. This was followed by the presentation of exome sequencing data in February 2023, which demonstrated an accuracy Phred quality score of one in ten thousand as the base error rate. Sequanta Technologies has conducted multiple verifications on the Element AVITI platform’s cluster analysis, confirming its ability to generate good clustering results with clear cell population differentiation and boundaries. This capability allows for the acquisition of accurate and high-quality single-cell data and analysis results.
Enhancing Single-Cell Sequencing Capabilities
The collaboration between Sequanta Technologies and Element Biosciences is set to significantly advance the field of single-cell sequencing. The integration of the AVITI system into Sequanta’s operations will enable deeper insights into cellular biology, driving innovation in research and clinical services.-Fineline Info & Tech
